Despite numerous studies demonstrating an association between the upregulation of B7H3 expression and poor prognosis and higher recurrence rates, the prognostic potential of B7H3 needs further clarification regarding different cancer types, patient populations, and methods for measuring B7H3 expression. This evidence concerns the gene CD276 and cancer.